Stoke Therapeutics (STOK) Profit After Tax (2018 - 2026)

Stoke Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 144.3% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$169.8 million (down 437.7% YoY), while the FY2025 annual figure was -$6.9 million, up 92.26% from the prior year.
• Profit After Tax was -$50.0 million for Q1 2026 at Stoke Therapeutics, up from -$57.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $112.9 million in Q1 2025 to a low of -$57.9 million in Q4 2025.
• Historically, Profit After Tax has averaged -$20.7 million across 5 years, with a median of -$25.7 million in 2024.
• Biggest YoY gain for Profit After Tax was 527.99% in 2025; the steepest drop was 452.7% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$25.7 million in 2022, then slipped by 5.08% to -$27.0 million in 2023, then soared by 61.12% to -$10.5 million in 2024, then tumbled by 452.7% to -$57.9 million in 2025, then rose by 13.69% to -$50.0 million in 2026.
• The last three Profit After Tax figures came in at -$50.0 million (Q1 2026), -$57.9 million (Q4 2025), and -$38.3 million (Q3 2025), per Business Quant data.